Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single-dose escalation study of LY2562175 in healthy subjects
NL-OMON33901Phase 1Active, not recruiting
- Sponsor
- Chorus Life Sciences
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TERN-101 in dyslipidemia and hypercholesterolemia (2 arms), sponsored by Chorus Life Sciences. Primary endpoints: Plasma LY2562175 concentrations, Pharmacokinetic parameters and 5 more. Started Mar 2009; status: active, not recruiting.
02
Drugs
TERN-101
03
Conditions
dyslipidemiahypercholesterolemia
Beyond the preview
Go deeper on NL-OMON33901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33901.